Clinical trials that focus on specific types of neuroendocrine neoplasms — heterogeneous tumors that can occur anywhere in the body — will be more likely to enhance drug development for these tumors, Vanderbilt physicians assert.
Satya Das, MD, has been awarded a $300,000 grant for a two-year period by the Neuroendocrine Tumor Research Foundation.
Accessibility Tools